TY  - JOUR
AU  - Lehtinen, Matti
AU  - van Damme, Pierre
AU  - Beddows, Simon
AU  - Pinto, Ligia A
AU  - Mariz, Filipe
AU  - Gray, Penelope
AU  - Dillner, Joakim
TI  - Scientific approaches to defining HPV vaccine-induced protective immunity.
JO  - International journal of cancer
VL  - 156
IS  - 10
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2025-00372
SP  - 1848-1857
PY  - 2025
N1  - Division of Infections and Cancer,Deutsches Krebsforschungszentrum, /  2025 May 15;156(10):1848-1857 / AG Martin Müller
AB  - Seventeen years after the licensure of prophylactic human papillomavirus (HPV) L1 virus-like-particle vaccines, a defined antibody level that correlates with vaccine-induced protection against HPV infections and associated neoplasia is missing. In contrast, correlates of protection have been defined for many viral vaccines, including for the hepatitis B virus (HBV) vaccine. This review includes lessons learned from vaccination against HBV and the use of an established protective HBV surface antigen antibody level: 10 mIU/mL, an overview of HPV infection-induced and HPV vaccine-induced antibody responses, successful efforts to establish international standardization of serological reagents and associated tools, and 15-year vigilance of HPV vaccine-induced antibody levels in a vaccination cohort against breakthrough infections. This report identifies progress but also gaps on the journey toward the definition of a HPV vaccine-induced correlate of protection.
KW  - antibody (Other)
KW  - cancer (Other)
KW  - hepatitis B virus (Other)
KW  - human papillomavirus (Other)
KW  - vaccine (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39945620
DO  - DOI:10.1002/ijc.35345
UR  - https://inrepo02.dkfz.de/record/298938
ER  -